HSPD1 and neoplasm: Terminal tumor measurements confirmed an 80.6% decrease in sh-HSPD1 xenograft mass (P < 0.01) (Fig. 2P), with gross morphological analysis demonstrating markedly diminished tumor sizes in the knockdown group (Fig. 2N).